Feasibility of ex vivo gene therapy for neurological disorders using the new retroviral vector GCDNsap packaged in the vesicular stomatitis virus G protein

This publication has 15 references indexed in Scilit:

• Simplified Retroviral Vector GCsap with Murine Stem Cell Virus Long Terminal Repeat Allows High and Continued Expression of Enhanced Green Fluorescent Protein by Human Hematopoietic Progenitors Engrafted in Nonobese Diabetic/Severe Combined Immunodeficient Mice
  Human Gene Therapy, 2001
• Therapeutic Potential of Neurotrophic Factors and Neural Stem Cells Against Ischemic Brain Injury
  Journal of Cerebral Blood Flow & Metabolism, 2000
• Cell replacement therapies for central nervous system disorders
  Nature Neuroscience, 2000
• Long-Term Survival of Human Central Nervous System Progenitor Cells Transplanted into a Rat Model of Parkinson's Disease
  Experimental Neurology, 1997
• A stable human-derived packaging cell line for production of high titer retrovirus/vesicular stomatitis virus G pseudotypes.
  Proceedings of the National Academy of Sciences, 1996
• Clonal and Population Analyses Demonstrate That an EGF-Responsive Mammalian Embryonic CNS Precursor Is a Stem Cell
  Developmental Biology, 1996
• Genetically modified skin fibroblasts persist long after transplantation but gradually inactivate introduced genes.
  Proceedings of the National Academy of Sciences, 1991
• Negative control region at the 5' end of murine leukemia virus long terminal repeats.
  Molecular and Cellular Biology, 1989
• Non-function of a Moloney murine leukaemia virus regulatory sequence in F9 embryonal carcinoma cells
  Nature, 1984
• Inhibition of VSV binding and infectivity by phosphatidylserine: Is phosphatidylserine a VSV-binding site?
  Cell, 1983